WikiTrademarks - Search, analyse, and monitor trademark applications.

Trademark: THE INTRATUMORAL IMMUNOTHERAPY COMPANY

Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io

Tweet this

Track updates on THE INTRATUMORAL IMMUNOTHERAPY COMPANY

Mark Identification

Proof of use for THE INTRATUMORAL IMMUNOTHERAPY COMPANY

We do not have any records of a proof of use for THE INTRATUMORAL IMMUNOTHERAPY COMPANY at this moment.

Click here to add a proof of use for THE INTRATUMORAL IMMUNOTHERAPY COMPANY

Possible trademark infringements of THE INTRATUMORAL IMMUNOTHERAPY COMPANY

Basic Information about THE INTRATUMORAL IMMUNOTHERAPY COMPANY

Serial Number
90491212
Filing Date
27 Jan 2021
Mark Drawing Code
4

Classifications

Declare the trademark use of THE INTRATUMORAL IMMUNOTHERAPY COMPANY on the blockchain with WikiTrademarks.io.

First use of THE INTRATUMORAL IMMUNOTHERAPY COMPANY anywhere
THE INTRATUMORAL IMMUNOTHERAPY COMPANY was first used on 01 Nov 2020 for the primary classification of goods and services, international, 042 (Computer, scientific & legal)
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
042
US Codes
100; 101

Who owns THE INTRATUMORAL IMMUNOTHERAPY COMPANY?

1. Syncromune, Inc. Fort Lauderdale FL

Correspondent

Jessica L. Rothstein
Goodwin Procter LLP
620 Eighth Avenue
New York NY 10018

Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io

Tweet this

Track updates on THE INTRATUMORAL IMMUNOTHERAPY COMPANY